Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > How does Accelerated Approval work

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 19, 2024 2:50pm

57 Views

Post# 36320315

RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

accelerated approval IS conditional itntdf...!! It grants marketing authorisation for 1 year... whilst a an ongoing study is conducted.

The 180 patient data will still be needed to support accelerated approval... so 2 years starting from H1 2025. which is still better than 4 years waiting to obtain OS data.

IF AA were to be possible in just a few months, the pps would be going vertical by now...

ONCY has no partner (forget Adlai Nortye, they're no longer interested), and with no partner, no money, no money = no trial..

End of ONCY.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project